<DOC>
	<DOC>NCT00189670</DOC>
	<brief_summary>To screen a dose-dense arm to be used in a future large scale phase III trial. Primary endpoint is safety; secondary endpoints are disease free survival and overall survival. A total of 100 patients were included.</brief_summary>
	<brief_title>Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patient with histologically proven breast cancer Surgical resection performed with clear margins (R0 resection) At least 1 histologically proven involved axillary node ER + or ER Interval between surgery (2nd surgical procedure in case of multiple procedures) and randomization inferior to 60 days Aged over 18 years, and more than 10year life expectancy ECOG performance status 01 Signed informed consent form prior to randomization Bilateral breast cancer Inflammatory breast cancer Personal history of breast cancer Immunohistochemical only node involvement Intraductal breast cancer Distant metastases Contraindication to any drug contained in the chemotherapy regimens Any serious active disease or comorbid medical condition including recent history of severe sepsis and digestive inflammatory disease Poor renal function (creatinin level &gt; 120 micromol/L), poor hepatic function (total bilirubin level &gt; 1 UNL), transaminases &gt; 2.5 UNL) Poor bone marrow reserve as defined by neutrophils &lt; 1.5 G/L or platelets &lt; 100 G/L; Hemoglobin &lt; 10 G/dL Poor contractile cardiac function (LVEF &lt; 50%) Coronary disease Any history of cancer during the last 5 years, with the exception of basal cell carcinomas or stage 0 (in situ) cervical carcinoma Pregnancy or breast feeding Absence of contraception in non menopausal women Adult patient unable to give informed consent because of intellectual impairment Concomitant participation to another trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>